Naturally Immune People Develop Ultrapotent Antibodies Against Variants


Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

Defenses against SARS-CoV-2 variants

Our key defense against the COVID-19 pandemic is neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus elicited by natural infection or vaccination. Recent emerging viral variants have raised concern because of their potential to escape antibody neutralization. Wang et al. identified four antibodies from early-outbreak convalescent donors that are potent against 23 variants, including variants of concern, and characterized their binding to the spike protein of SARS-CoV-2. Yuan et al. examined the impact of emerging mutations in the receptor-binding domain of the spike protein on binding to the host receptor ACE2 and to a range of antibodies. These studies may be helpful for developing more broadly effective vaccines and therapeutic antibodies. READ FULL STUDY

Science, abh1766, this issue p. eabh1766, abh1139, this issue p. 818